

Fax completed form to: (855) 840-1678
If this is an URGENT request, please call (800) 882-4462 (800.88.CIGNA)

## Blincyto (Blinatumomab)

PHYSICIAN INFORMATION		PATIENT INFORMATION					
* Physician Name: Dr. Oncoso		*Due to privacy regulations we will not be able to respond via fax with the outcome of our review unless all asterisked (*) items on this					
Specialty: Pediatric Hematology and Oncology * DEA, NF 54678	PI or TIN: 892394	form are completed.*					
Office Contact Person: Mrs. Dana Smith		* Patient Name: Lucas Little					
Office Phone: 555-324-7878		* Cigna ID: 345987					
Office Fax: 555-324-7877		* Patient Street Address: 28 Dearborn St					
Office Street Address: 27 W State St		City: Chicago	State	: IL	Zip: 60602		
City: Chicago State: IL	Zip: 60601	Patient Phone: 555-360-8746	5				
Urgency:  ☐ Standard  Urgent (In checking this box, I attest to the fact that applying the standard review time frame may seriously jeopardize the customer's life, health, or ability to regain maximum function)							
Medication requested:  ☐ Cisplatin 50mg powder for injection ☐ Cisplatin 100mg/100ml solution for injection ☐ Cisplatin 1mg/1ml solution for injection ☐ Cisplatin 200mg/200ml solution for injection ☐ Cisplatin 50mg/50ml solution for injection ☐ Cisplatin 50mg/50ml solution for injection ☐ Other (please specify): Blincyto							
ICD10:							
Dose: 28mcg/day Frequency of therapy: Induction cycle 1 Duration of Therapy:  Days 1-28: 28 mcg/day Duration of Therapy:							
What is your patient's current height? 117cm What is your patient's current weight? Based on clinical response, up to 6 months 30kg							
Is the requested medication for a chronic or long-term condition for which the prescription medication may be necessary for the life of the patient?							
Where will this medication be obtained?  ☐ Accredo Specialty Pharmacy** ☐ Hospital Outpatient ☐ Retail pharmacy ☐ Other (please specify):  **Medication orders can be placed with Accredo via E-prescribe - Accredo (1620 Century Center Pkwy, Memphis, TN 38134-8822   NCPDP 4436920), Fax 888.302.1028, or Verbal 866.759.1557						acy	
Facility and/or doctor dispensing and administering medication:							
Facility Name: Address (City, State, Zip Code):	State:	Tax ID#:					
Is the patient a candidate for home infusion	1?				🖊 Yes 🗌 I	No	
Does the physician have an in-office infusion				☑Yes 🔲 I	No		
Where will this drug be administered Patient's Home Physician's Office Hospital Outpatient Other (please specifications of the Control of the	Infusion center in fy): home with home	e health		·			
NOTE: Per some Cigna plans, infusion of medication MUST occur in the least intensive, medically appropriate setting.							
Is this patient a candidate for re-direction to an alternate setting (such as alternate infusion site, physician's office, home) with assistance of a Specialty Care Options Case Manager? (provide medical necessity rationale):							

Is the patient a candidate for home infusion?	Yes No 🗆					
Does the physician have an in-office infusion site?	Yes☑ No 🗆					
Clinical Information:						
Does your patient have a diagnosis of B-cell acute lymphoblastic leukemia (ALL)?	Yes ☑ No 🗌					
(if no) What is the diagnosis related to use?	Yes 🗌 No 🗌					
Is your patient in either their first or second complete remission?	Yes No 🗌					
(if yes) Does your patient have minimal residual disease (MRD)?	Yes 🗌 No 🗌					
Does your patient have Philadelphia chromosome -positive or -negative ALL  Ph+ (positive) Ph- (negative) Unknown						
(if Ph+) Has your patient failed treatment with tyrosine kinase inhibitor therapy (for example: imatinib [Gleevec], dasatinib [Sprycel], nilotinib [Tasigna])? Yes ☐ No [						
(if PH-) Is your patient in the consolidation phase of multiphase chemotherapy?	Yes 🗌 No 🖊					
Does your patient have relapsed or refractory disease?	Yes <b>∕</b> No □					
Has your patient already started treatment with Blincyto?	Yes 🗌 No 🗹					
How many treatment cycles has your patient received to date? 1 standard induction and consolidation cycle, now in maintenance phase						
Is the total number of treatment cycles the patient will receive more than 9?	Yes 🗌 No 🗹					
Please Provide any Additional Pertinent Clinical Information: (please include disease stage, prior therapy, performance status, and names/doses/admin schedule of any agents to be used concurrently):						
Please see attached clinical documentation, laboratory results and pathology reports						
Attestation: I attest the information provided is true and accurate to the best of my knowledge. I understand that the insurer its designees may perform a routine audit and request the medical information necessary to verify the accordance of the information reported on this form.  Prescriber Signature:  Date: 10/15/2	ccuracy of the					
Save Time! Submit Online at: <a href="https://www.covermymeds.com/main/prior-authorization-forms/cigna/">www.covermymeds.com/main/prior-authorization-forms/cigna/</a> or via SureScripts in your EHR.						
	. ,					

Our standard response time for prescription drug coverage requests is 5 business days. If your request is urgent, it is important that you call us to expedite the request. View our Prescription Drug List and Coverage Policies online at cigna.com.

V091524